ACOR | Acorda Therapeutics (NASDAQ:ACOR) Shares Gap Down to $1.10

Acorda Therapeutics, Inc.(NASDAQ:ACOR)’s share price gapped down before the market opened on Tuesday .The stock had previously closed at $1.10, but opened at $1.03.Acorda Therapeutics shares last traded at $1.02, with a volume of 99,527 shares trading hands.A number of brokerages have commented on ACOR.Jefferies Financial Group restated a “hold” […]Transcript Daily

ACOR | Acorda Therapeutics (NASDAQ:ACOR) Upgraded at ValuEngine

ValuEngine upgraded shares of Acorda Therapeutics (NASDAQ:ACOR) from a hold rating to a buy rating in a report released on Monday, ValuEngine reports.ACOR has been the subject of several other reports.Zacks Investment Research lowered shares of Acorda Therapeutics from a hold rating to a sell rating in a research report on Wednesday, October […]Transcript Daily

ACOR | Acorda Therapeutics (NASDAQ:ACOR) Trading Down 7%

Acorda Therapeutics, Inc.(NASDAQ:ACOR)’s share price fell 7% on Thursday .The company traded as low as $0.77 and last traded at $0.87.5,770,156 shares traded hands during trading, an increase of 74% from the average session volume of 3,310,928 shares.The stock had previously closed at $0.94.Several research analysts have weighed in on […]The Olympia Report

ACOR | Wedbush Brokers Raise Earnings Estimates for Acorda Therapeutics, Inc. (NASDAQ:ACOR)

Acorda Therapeutics, Inc.(NASDAQ:ACOR) – Stock analysts at Wedbush boosted their Q3 2020 EPS estimates for Acorda Therapeutics in a research note issued on Monday, October 19th.Wedbush analyst L.Chico now anticipates that the biopharmaceutical company will post earnings per share of ($0.62) for the quarter, up from their previous forecast of ($0.66).Wedbush […] Dakota Financial News

ACOR | Zacks Investment Research Downgrades Acorda Therapeutics (NASDAQ:ACOR) to Sell

Acorda Therapeutics (NASDAQ:ACOR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday, Zacks.com reports.According to Zacks, “Acorda Therapeutics, Inc.is a biotechnology company developing and commercializing neurology therapies for Parkinson’s disease, migraine and multiple sclerosis.Acorda has a pipeline of novel neurological […]The Olympia Report